Related Experiment Videos
Experimental trials with Gd(DO3A)--a nonionic magnetic resonance contrast agent
V M Runge1, D M Kaufman, M L Wood
1Department of Radiology, Tufts-New England Medical Center Hospitals, Boston, MA 02111.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
|January 1, 1989
Summary
Gadolinium(DO3A) effectively enhances intracerebral gliomas in rats, aiding tumor identification. This new nonionic MRI contrast agent shows comparable or superior renal enhancement versus established agents.
Area of Science:
- Medical Imaging
- Radiology
- Oncology
Background:
- Nonionic MRI contrast agents offer potential advantages in patient safety.
- Gadolinium-based contrast agents are essential for MRI diagnostics.
- Evaluating novel agents like Gadolinium(DO3A) is crucial for advancing imaging techniques.
Purpose of the Study:
- To assess the efficacy of Gadolinium(DO3A) as an MRI contrast agent in vivo.
- To evaluate Gadolinium(DO3A)'s ability to enhance intracerebral gliomas in a rat model.
- To compare the renal enhancement properties of Gadolinium(DO3A) with existing contrast agents.
Main Methods:
- In vivo evaluation in a rat model.
- Intracerebral glioma enhancement study following Gadolinium(DO3A) injection.
- Comparative renal enhancement studies using disodium Gd(DTPA)2-, sodium-Gd(DOTA)-, and Gd(DO3A).
Main Results:
- Gadolinium(DO3A) administration enhanced intracerebral glioma tissue with an altered blood-brain barrier.
- This enhancement facilitated the identification of the neoplastic lesion.
- Comparative studies showed Gadolinium(DO3A) provided equal or superior enhancement of the normal renal medulla.
Conclusions:
- Gadolinium(DO3A) demonstrates potential as an effective MRI contrast agent for visualizing brain tumors.
- The agent's performance in enhancing renal medulla is comparable or superior to existing agents.
- Further research into Gadolinium(DO3A) may lead to improved diagnostic capabilities in MRI.